Whiteweed (Ageratum conyzoides L.): A Comprehensive Reference Article
1. Identity and Botanical Classification
Scientific Name, Taxonomy, and Common Synonyms
Ageratum conyzoides (L.) — bearing the common English names billygoat-weed, chick weed, goatweed, and whiteweed — is native to Tropical America, especially Brazil, and is an invasive weed in many other regions. The name whiteweed is the accepted common name used in the United States for the genus Ageratum as a whole, and for A. conyzoides in particular. The genus Ageratum (pronounced /əˈdʒɛrətəm/) comprises 40 to 60 tropical and warm-temperate flowering annuals and perennials belonging to the family Asteraceae, tribe Eupatorieae. Most species are native to Central America and Mexico, but four are native to the United States.
The species is also known as Billygoat weed, Goatweed, or Tropical Whiteweed. Its taxonomic serial number (TSN) in the Integrated Taxonomic Information System is 36481. The Florida Plant Atlas records the full citation as Ageratum L., Family ASTERACEAE, with common name WHITEWEED, Order ASTERALES.
Morphology and Habitat
Native to Tropical America, specifically Brazil, this herb stands 2–3 ft high, with ovate leaves 2–6 cm long and white to mauve flowers. Ageratum conyzoides is an annual growing to 1 m (3 ft 3 in). It is in leaf from May to October and in flower from July to September. The species is hermaphrodite (has both male and female organs) and is pollinated by insects.
Ageratum conyzoides L. (Family—Asteraceae) is an annual aromatic invasive herb, mainly distributed over the tropical and subtropical regions of the world. It has a USDA hardiness of 8–11 and is a common inhabitant of cultivated grounds around the tropics within 20° of the Equator. It grows best in light, medium, or heavy soils but cannot tolerate shade. A South American native, tropical whiteweed is an escapee from cultivation in parts of the United States, and may also have been inadvertently imported in ships' ballast.
Common Preparations and Forms
The whole plant, its aerial parts, leaves, flowers, stems, and roots are all employed medicinally. Its history of indigenous remedial uses includes use as a wound dressing, an antimicrobial, and a mouthwash, as well as in treatment of dysentery, diarrhea, and skin diseases. In Brazil, teas made from A. conyzoides L. are used as anti-inflammatory, analgesic, and anti-diarrheic agents. The plant's juice, whether from a fresh or dried plant, is also extensively used in the treatment of allergic rhinitis and sinusitis. Modern commercial preparations include standardized ethanolic or hydroethanolic extracts, encapsulated powders, topical gels, emulsified concentrates, and nanoemulgels. Various herbal or polyherbal dosage forms of A. conyzoides such as gels, emulsified concentrate, and nanoemulgel have shown improved wound healing, anti-inflammatory, and antimicrobial properties.
2. Traditional and Historical Use
Overview and Geographic Spread
Ageratum conyzoides L. is an annual herb with a long history of traditional medicinal uses in many countries in the world, especially in the tropical and subtropical regions. It is an integral part of traditional medicine in Africa, Asia, and South America, where it is used to treat a wide range of diseases, such as diabetes, skin diseases, respiratory disorders, inflammation, burns, wounds, diarrhea, fever, muscle pain, reproductive problems, leprosy, and other ailments.
Africa
A. conyzoides has imparted numerous ethnomedicinal uses because it has been used to cure various ailments that include leprosy, skin disorders, sleeping sickness, rheumatism, headaches, dyspnea, toothache, pneumonia, and many more. A. conyzoides is a tropical plant very common in West Africa, where it has been used to treat inflammatory disorders. Historical pharmacopeias from West Africa — including early Senegalese and East African records — document its antibacterial use in wound care and its role in managing gastrointestinal illness.
Asia — India and China
In Asia, particularly in India and China, A. conyzoides is used in Ayurvedic and traditional Chinese medicine for its antimicrobial and anti-rheumatic properties. This mechanistic understanding validates its ethnomedicinal use for arthritis, rheumatism, and fever management.
South America and the Caribbean
Ageratum conyzoides L. has traditionally been used in the Caribbean for prostate and urinary health. The well-established popular use of Ageratum conyzoides has led to its inclusion in a category of medicinal crude drugs created by the Brazilian Health Surveillance Agency. In Brazil, teas made from A. conyzoides L. are used as anti-inflammatory, analgesic, and anti-diarrheic agents.
Summary of Traditional Indications
- Ageratum conyzoides has been known since antiquity for its medicinal properties and effectiveness in the treatment of various ailments ranging from skin disease, fever, to relief of colic, flatulence, dysentery, and diarrhea.
- The plant's juice is used in the treatment of allergic rhinitis and sinusitis. It also assists in controlling post-partum uterine haemorrhage and can combat dysentery and diarrhea.
- Traditionally used for skin disorders, gastrointestinal issues, headaches, rheumatism, pneumonia, and wound healing.
3. Key Constituents and Active Compounds
Overview of Phytochemistry
A wide range of chemical compounds including alkaloids, flavonoids, chromenes, benzofurans, and terpenoids have been isolated from this species. Extracts and metabolites from this plant have been found to possess pharmacological and insecticidal activities. The preliminary phytochemical screening analysis established that the plant contained alkaloids, glycosides, phenols, flavonoids, saponins, tannins, steroids, and triterpenes.
Chromenes and Precocenes
The most predominant compounds of the essential oil are known to be 7-methoxy-2,2-dimethylchromene (precocene I) and the 6,7-dimethoxy derivative ageratochromene (precocene II). The essential oil has been characterized by the presence of high percentages of precocene I (34.4%) and β-caryophyllene (24.6%), as well as small amounts of precocene II. Precocenes have attracted significant pharmacological interest for their anti-juvenile-hormone (antigonadotropic) activity in insects, as well as contributions to the plant's analgesic and anti-inflammatory profile in mammalian systems. The chromene compounds studied as analgesic agents correspond with in silico predictions in which precocene I, precocene II, and VMDC performed relatively good energy bindings at the COX-2 receptor.
Flavonoids
Investigations have reported the presence of a vast variety of phytoconstituents in the herb's essential oil, including flavonoids (kaempferol, quercetin, quercetin-3-rhamnopiranoside). The anti-inflammatory potential of A. conyzoides has been linked to its flavonoid constituents, particularly quercetin and kaempferol, which modulate key inflammatory markers including TNF-α, IL-6, and NF-κB. Methoxyflavonoids, especially 5′-methoxynobiletin, are the most abundant compounds in a crude ethanolic extract of the aerial parts, as identified by UPLC-HRMS. Polymethoxyflavones studied as anti-inflammatory agents exhibit better binding energy with COX-2 than chromene and other ligands.
Alkaloids — Including Pyrrolizidine Alkaloids
The herb's essential oil contains benzofurans (precocene I, precocene II, and ageratochromene dimer), coumarin, chromene, flavonoids, alkaloids (caffeic acid, echinatine, phytol, and pyrrolizidine alkaloids), sterols (stigmasterol, β-sitosterol, and friedeline), terpenes (α-pinene, β-pinene), and eugenol, varying in their concentrations from one place to another.
The pyrrolizidine alkaloids lycopsamine, dihydrolycopsamine, and acetyl-lycopsamine and their N-oxides were detected in analyzed aqueous extracts, with lycopsamine and its N-oxide being known hepatotoxins and tumorigens. These pyrrolizidine alkaloids — lycopsamine, dihydrolycopsamine, and acetyl-lycopsamine and their N-oxides — have been detected in both commercial and wild-harvested Brazilian plant material prepared as tea.
Terpenoids, Sterols, and Other Constituents
A number of phytoconstituents have been scrutinized, including alkaloids, flavonoids, terpenes, chromenes, and sterols from almost every part of this plant. The screening of phytochemicals in root extracts indicated the existence of terpenoids, alkaloids, coumarins, sterols, flavonoids, and glycosides. Ageratum conyzoides is known for its unique composition. It contains 0.7–2.0% essential oil, alkaloids, and saponins, which contribute to its anti-inflammatory and antiallergic properties.
Established Mechanisms of Action
- Anti-inflammatory pathway modulation: Studies highlight the plant's capacity to modulate inflammatory pathways (TNF-α/NF-κB) and its ability to stimulate collagen production during wound repair.
- 5α-reductase inhibition: A. conyzoides has been found to inhibit the 5α-reductase gene expression in human prostate cells and mitigate symptoms related to benign prostatic hypertrophy (BPH).
- Trichogenic (hair-growth) signaling: Human follicle dermal papilla cells treated with a standardized A. conyzoides extract (ACE) showed effects on 5α-reductase activity, estrogen receptor (ERα/ERβ) signaling, and activation of Wnt/β-catenin and MAPK pathways. In HFDPCs, ACE inhibited 5α-reductase activity, modulated ERα and ERβ signaling, and activated Wnt/β-catenin and MAPK pathways.
- Antidiabetic (hypoglycemic) activity: In the antidiabetic activity, the hypoglycemic effect of Ageratum conyzoides could be due to the presence of chromene compounds.
- COX-2 inhibition (analgesia): The chromene compounds studied as analgesic agents correspond with in silico prediction, in which precocene I, precocene II, and VMDC performed relatively good energy bindings at COX-2.
- Antimicrobial action: Flavonoids such as polymethoxyflavone were studied as antibacterial agents against E. coli, which could be due to the inhibition of 4-diphosphodicytidyl-2-C-methylerythritol synthase.
4. Scientific Evidence by Area of Use
4.1 Benign Prostatic Hyperplasia (BPH)
The strongest body of clinical evidence for whiteweed relates to benign prostatic hyperplasia. A double-blind, randomized, placebo-controlled clinical trial assessed the efficacy and safety of Ageratum conyzoides in treating benign prostatic hypertrophy (BPH). In this study, 109 men with medically diagnosed BPH, aged 41–76 years, were administered the investigational product, A. conyzoides extract at a dose of 250 mg/day or placebo, once daily for 12 weeks. The primary outcome measures were the International Prostate Symptom Score (IPSS), daily urinary frequency, and safety evaluations.
Supporting preclinical work corroborates these clinical findings. Rats were subcutaneously administered testosterone propionate (3 mg/kg) to induce BPH and concurrently orally administered ACE (20, 50, and 100 mg/kg) daily for 42 days. ACE markedly improved BPH characteristics, including prostate weight, prostate index, and epithelial thickness, while also suppressing androgens and related hormones.
Evidence characterization: The double-blind, randomized, placebo-controlled trial in 109 men represents meaningful Level II clinical evidence for BPH. However, this is a single trial, and replication by independent groups is needed before conclusions about efficacy can be considered robust.
4.2 Hair Loss (Androgenetic Alopecia)
A pilot, open-label, randomized, parallel, and in vitro study published in the Journal of Cosmetology and Trichology assessed the efficacy and safety of a hair loss formulation, with results showing it as an effective treatment option. The study was aimed to determine the effect of an Ageratum conyzoides extract on the gene expression of 5α-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT), a major driver of androgenetic alopecia (pattern hair loss), along with another likely cause — the release of Prostaglandin D2 (PGD2) — in human hair dermal papilla cells (HHDPC).
More recent mechanistic research has added depth. Research investigated the trichogenic potential and underlying mechanisms of a standardized Ageratum conyzoides extract (ACE) using human follicle dermal papilla cells (HFDPCs) and C57BL/6 mice as models. In vivo, C57BL/6 mice were administered ACE orally, and hair regrowth, follicle number and depth, and histological changes were measured. In HFDPCs, ACE inhibited 5α-reductase activity, modulated ERα and ERβ signaling, and activated Wnt/β-catenin and MAPK pathways. Previous studies in humans suggest that Ageratum conyzoides promotes hair growth and reduces hair loss. However, its underlying mechanisms remain incompletely understood.
Evidence characterization: Evidence for hair loss consists of a pilot open-label clinical study (limited by design: no blinding, small scale), supported by in vitro cell studies and mouse models. This evidence is preliminary and exploratory; large-scale, blinded, placebo-controlled human trials are not yet available.
4.3 Wound Healing
A study aimed to observe the efficacy of topical administration of an ethanolic extract of Ageratum conyzoides on cutaneous wound healing in rats. An ethanolic extract of A. conyzoides was prepared, and its wound-healing efficacy on rats was studied. An open excision wound was made on the back of each rat, and 200 µL (40 mg/kg body weight) of the extract was applied topically once daily to the treated wounds. The extract increased cellular proliferation and collagen synthesis. Wounds treated with the extract were found to heal much faster, based on the improved rates of epithelialization and wound contraction, and on histopathological results. A 40% increase in the tensile strength of the treated tissue was seen.
Studies highlight the plant's capacity to modulate inflammatory pathways (TNF-α/NF-κB) and its ability to stimulate collagen production during wound repair. Extract of goat weed could be developed into a polyherbal formulation as a wound-healing agent through a topical route. This formulation is composed of Ageratum conyzoides, Ficus religiosa, Curcuma longa, and Tamarindus indica. The result showed that the polyherbal formulation has a good wound-healing effect in rats.
Evidence characterization: Wound-healing evidence is primarily preclinical (animal models and in vitro cell systems). No controlled human clinical trials specifically evaluating wound healing with standardized A. conyzoides monotherapy were identified in the peer-reviewed literature. Evidence should be considered preliminary.
4.4 Anti-inflammatory Activity
Studies demonstrate that A. conyzoides L. exerts anti-inflammatory properties by inhibiting leukocyte influx and protein concentration of the exudate, as well as reducing the levels of several pro-inflammatory mediators. The anti-inflammatory potential of A. conyzoides has been linked to its flavonoid constituents, particularly quercetin and kaempferol, which modulate key inflammatory markers including TNF-α, IL-6, and NF-κB.
Evidence characterization: Anti-inflammatory effects are well-characterized at the preclinical and mechanistic levels (animal and in vitro studies). Human clinical evidence is limited; available clinical work is primarily secondary to BPH trials, which include inflammation-related endpoints. The overall evidence strength for anti-inflammatory use as a standalone indication is preliminary.
4.5 Antimicrobial (Antibacterial and Antifungal) Activity
Phytoconstituents of A. conyzoides have shown diverse pharmacological properties including antimicrobial, anti-inflammatory, analgesic, antioxidant, anticancer, antiprotozoal, antidiabetic, and spasmolytic activities. Using the disk diffusion method, the essential oil of A. conyzoides showed weak activity against Staphylococcus aureus, S. epidermidis, Streptococcus faecalis, Proteus vulgaris, and Cladosporium cladosporioides, and was inactive against Escherichia coli, Candida albicans, Cryptococcus neoformans, Aspergillus niger, and A. fumigatus.
The results of root extract studies indicated a reasonable antibacterial (against gram-negative and gram-positive bacteria) and antifungal potential. The antibacterial activity of the ethanolic extract was highest against all four strains of bacteria tested and was also comparable to the standard medicines used.
Evidence characterization: Antimicrobial evidence is primarily in vitro. Results for antibacterial activity are generally more encouraging than for antifungal activity. No human clinical trials on infectious disease have been identified. Evidence is at the level of bioassay and preclinical research.
4.6 Antidiabetic Activity
In antidiabetic activity, the hypoglycemic effect of Ageratum conyzoides could be due to the presence of chromene compounds. These secondary metabolites are claimed to have diverse medicinal properties, including antidiabetic, antimicrobial, anti-inflammatory, antioxidant, anticancer, and wound-healing properties.
Evidence characterization: Antidiabetic evidence is based on animal models (rodent) and in silico predictions. No controlled human clinical studies on blood glucose management have been identified. Evidence is preliminary and mechanistic.
4.7 Antimalarial Activity
Ageratum conyzoides compounds have been extensively studied for pharmacological activity as antimalarial agents. The interaction of pyrrolizidine alkaloids with ornithine delta-aminotransferase does not appear to be related to its antimalarial property; therefore, other proteins or genes expressed by Plasmodium falciparum are likely being targeted.
Evidence characterization: Antimalarial evidence is at the in vitro and in silico level. No human clinical trials on malaria have been identified. Evidence is exploratory.
4.8 Allergic Rhinitis and Sinusitis
The plant's juice, whether from a fresh or dried plant, is extensively used in the treatment of allergic rhinitis and sinusitis in traditional ethnomedicine. The anti-inflammatory and antiallergic properties attributed to the essential oil fraction and flavonoid constituents are proposed as the mechanism. The plant's composition — including 0.7–2.0% essential oil, alkaloids, and saponins — is thought to contribute to the anti-inflammatory and antiallergic properties.
Evidence characterization: Use for rhinitis and sinusitis remains documented only at the level of traditional ethnomedicine and informal pharmacological rationale. No randomized controlled trials in this indication have been identified.
5. Body Systems and Health Areas Associated with Whiteweed
- Genitourinary system: BPH, urinary tract disorders, post-partum uterine haemorrhage (the plant assists in controlling post-partum uterine haemorrhage)
- Integumentary system: Wound healing, skin diseases, leprosy, burns
- Musculoskeletal / rheumatological system: Arthritis, rheumatism, muscle pain
- Gastrointestinal system: Dysentery, diarrhea, colic, flatulence
- Respiratory system: Allergic rhinitis, sinusitis, respiratory disorders, pneumonia, dyspnea
- Endocrine / metabolic system: Hyperglycemia / diabetes management (preclinical only)
- Dermatological / trichological system: Hair loss (androgenetic alopecia)
- Infectious disease: Antimicrobial (bacterial, fungal, protozoan)
- Neurological system: Headache, analgesic use
- Fever management: Antipyretic use across multiple traditional systems
These phytoconstituents have shown diverse pharmacological properties including antimicrobial, anti-inflammatory, analgesic, antioxidant, anticancer, antiprotozoal, antidiabetic, spasmolytic, allelopathy, and many more.
6. Dosage Forms and Reported Dosages
Reported doses in the scientific literature vary substantially by formulation, route of administration, and intended use. The following dosages are reported directly from published studies:
- BPH — oral extract, human clinical trial: A. conyzoides extract at a dose of 250 mg/day, administered once daily for 12 weeks in 109 adult men aged 41–76 years.
- Wound healing — topical application, rat study: 200 µL (40 mg/kg body weight) of ethanolic A. conyzoides extract was applied topically once daily to treated wounds.
- BPH — oral extract, rat model: Rats were orally administered standardized ethanolic extract (ACE) at doses of 20, 50, and 100 mg/kg daily for 42 days.
- Traditional tea preparation (Brazil): Aqueous extracts of Ageratum conyzoides L. harvested in Brazil (commercial, flowering, and non-flowering samples) are prepared according to the prescribed method. No standardized dose for traditional tea has been formally validated in clinical guidance documents.
Even though many researchers have assessed the plant and its constituents for a safer approach, there is still a dearth of ample facts and figures required for an adequate inference about the dose required for a prompt action circumventing any toxicity issue.
7. Safety Considerations and Interactions
Pyrrolizidine Alkaloid Hepatotoxicity
The most significant and scientifically substantiated safety concern associated with A. conyzoides is its content of pyrrolizidine alkaloids (PAs). Ageratum belongs to the Eupatorieae tribe, Asteraceae, and is described as containing toxic pyrrolizidine alkaloids. The PAs lycopsamine, dihydrolycopsamine, and acetyl-lycopsamine and their N-oxides were detected in analyzed extracts, with lycopsamine and its N-oxide being known hepatotoxins and tumorigens.
Pyrrolizidine alkaloids, namely lycopsamine, dihydrolycopsamine, acetyl-lycopsamine, and their N-oxides, have been identified in alcoholic extracts of the plant, and an investigation confirmed the presence of PA in a tea (aqueous extract) of the aerial parts of A. conyzoides widely used in traditional medicine. Human cases of PA intoxication leading to hepatic damage — most often veno-occlusive disease — have been reported, with the liver being the first target organ in PA poisoning.
Hepatic Veno-Occlusive Disease
Hepatic veno-occlusive disease (HVOD) is a rare but severe condition characterized by the blockage of microscopic veins in the liver due to endothelial damage, leading to sub-endothelial thickening, edema, and fibrosis. Globally, the cause of HVOD is primarily associated with pyrrolizidine alkaloid ingestion, radiation therapy, and post-transplant reactions. In the Tigray region of Ethiopia, an outbreak of the disease has been linked with contaminated harvests containing PA-producing Ageratum conyzoides.
Organ Weight Changes in Animal Toxicology
Hepatotoxicity and other toxicologically significant findings have been reported in murine model evaluations of A. conyzoides ethanolic leaf extracts. In a 90-day repeated-dose oral toxicity study in Wistar rats, no significant effect on body weight was observed, but compared with the control group, relative weight of the liver, spleen, and kidney were significantly altered.
Regional Variation in PA Content
The occurrence or non-appearance of PAs fluctuates greatly from region to region. Some countries such as Belgium and Germany recommend the use of PAs within approved limits to ensure the clinical safety of patients. To date, there are no established safety guidelines on pyrrolizidine alkaloids-containing plants and their use in Brazil.
Tumorigenic Potential
Several species of Ageratum are toxic, containing pyrrolizidine alkaloids. Ageratum houstonianum and Ageratum conyzoides cause liver lesions and are tumorigenic. Pyrrolizidine alkaloids may cause hepatotoxicity at high doses.
Pollen Allergenicity
Members of the Asteraceae family are known producers of allergenic pollen. Despite its pharmacological promise, the presence of pyrrolizidine alkaloids presents hepatotoxicity risks, underscoring the need for standardized formulations.
PA-Reduced Standardized Extracts
The lack of standardized extraction methods and the limited nature of preclinical and clinical data justify further studies to validate efficacy and ensure the safety of therapeutic use. Future research priorities include well-structured clinical trials, nanoformulation development to improve bioavailability, and biotechnological approaches for optimized production.
Honey Contamination
Pyrrolizidine alkaloids have been analyzed in stingless bee honey, with Ageratum conyzoides identified as a botanical source. This represents an indirect route of exposure to PAs from the plant, beyond direct herbal preparations.
8. Overall Evidence Assessment
Overall, the available data corroborate many of the traditional uses of this plant. However, the lack of standardized extraction methods and the limited nature of preclinical and clinical data justify further studies to validate its efficacy and ensure the safety of its therapeutic use.
A. conyzoides contains diverse bioactive compounds such as flavonoids, alkaloids, terpenes, chromenes, and phenolic acids. These are associated with anti-inflammatory, antimicrobial, antidiabetic, anticancer, antioxidant, and wound-healing activities. In particular, flavonoids and chromenes contribute to the plant's antioxidant and anti-inflammatory effects, while pyrrolizidine alkaloids may cause hepatotoxicity at high doses. Overall, the available data corroborate many of the traditional uses of this plant. However, the lack of standardized extraction methods and the limited nature of preclinical and clinical data justify further studies to validate its efficacy and ensure the safety of its therapeutic use.
The most clinically advanced area is BPH, where a double-blind, randomized, placebo-controlled trial in humans has been published. All other applications — including wound healing, anti-inflammatory use, antidiabetic potential, and hair loss — remain at the preclinical or early pilot clinical stage as of the available peer-reviewed literature. The hepatotoxic risk from pyrrolizidine alkaloids is a serious and well-documented safety signal that must be considered in any evaluation of internal (oral) use.
References
Go back